Zeeli T, Padalon-Brauch G, Ellenbogen E, Gat A, Sarig O, Sprecher E
Department of Dermatology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
Department of Institute of Pathology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
Clin Exp Dermatol. 2015 Jun;40(4):367-72. doi: 10.1111/ced.12585. Epub 2015 Feb 16.
Pyogenic sterile arthritis, pyoderma gangrenosum and acne (PAPA) syndrome is a rare hereditary, autosomal dominant, auto-inflammatory disease caused by mutations in the PSTPIP1 gene, which encodes proline-serine-threonine phosphatase interacting protein 1. The fact that PSTPIP1 is involved in immune regulation provides a rationale for treatment of this rare disease with interleukin (IL)-1 signalling blocking agents.
We investigated a 33-year-old man with a long-standing history of ulcerative colitis, severe acne and recurrent skin ulcerations, and a 3-year history of a recalcitrant pustular rash.
We used direct sequencing to search for mutations in the PSTPIP1 gene.
Examination of biopsies obtained from pustules and skin ulcers revealed folliculitis and ulceration with a diffuse neutrophilic dermal infiltrate, consistent with a diagnosis of pyoderma gangrenosum. Because of the known association of acne and pyoderma gangrenosum in PAPA syndrome, we determined the entire coding sequence of the PSTPIP1 gene, and identified a hitherto unreported heterozygous mutation predicted to alter a highly conserved residue (p.G403R) and to be damaging to the protein function. Based on this finding, we initiated treatment with a human IL-1 receptor antagonist, anakinra, which led to a dramatic improvement in the patient's condition.
We describe a novel mutation in PSTPIP1 resulting in pyoderma gangrenosum, acne and ulcerative colitis. This novel constellation of clinical manifestations, which we term 'PAC syndrome', suggests the need to regroup all PSTPIP1-associated phenotypes under one aetiological group.
化脓性无菌性关节炎、坏疽性脓皮病和痤疮(PAPA)综合征是一种罕见的遗传性常染色体显性自身炎症性疾病,由PSTPIP1基因突变引起,该基因编码脯氨酸 - 丝氨酸 - 苏氨酸磷酸酶相互作用蛋白1。PSTPIP1参与免疫调节这一事实为使用白细胞介素(IL)-1信号阻断剂治疗这种罕见疾病提供了理论依据。
我们对一名33岁男性进行了研究,该患者有长期溃疡性结肠炎、重度痤疮和复发性皮肤溃疡病史,以及3年顽固性脓疱性皮疹病史。
我们采用直接测序法寻找PSTPIP1基因中的突变。
对脓疱和皮肤溃疡处活检组织的检查显示为毛囊炎和溃疡,伴有弥漫性中性粒细胞真皮浸润,符合坏疽性脓皮病的诊断。由于已知PAPA综合征中痤疮与坏疽性脓皮病有关联,我们测定了PSTPIP1基因的整个编码序列,并鉴定出一个此前未报道的杂合突变,该突变预计会改变一个高度保守的残基(p.G403R)并损害蛋白质功能。基于这一发现,我们开始使用人IL-1受体拮抗剂阿那白滞素进行治疗,这使患者的病情得到了显著改善。
我们描述了PSTPIP1基因中的一种新突变,该突变导致坏疽性脓皮病、痤疮和溃疡性结肠炎。这种新的临床表现组合,我们称之为“PAC综合征”,表明有必要将所有与PSTPIP1相关的表型重新归为一个病因组。